You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)完成配售3654.92萬股 淨籌25.28億港元用於藥物研發和管線擴充
格隆匯 06-23 20:44

格隆匯6月23日丨君實生物(01877.HK)宣佈,配售協議所載有關配售事項的全部先決條件均已獲達成(包括獲香港聯交所批准配售股份上市及買賣),且配售事項已於2021年6月23日落實完成。

於2021年6月23日,公司成功按配售價格每股H股70.18港元向至少六名承配人配發及發行合共3654.92萬股新H股,分別佔經發行配售股份而有所擴大的公司全部已發行H股及全部已發行股份約16.67%及4.01%。概無任何承配人在緊隨配售完成後成為公司的主要股東。配售事項所得款項總額合計約為25.65億港元,公司將收取的配售事項所得款項淨額合計約為25.28億港元。配售事項所得款項淨額擬由集團用於藥物研發和管線擴充、拓展商業化團隊、境內外投資、併購和業務發展以及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account